Table 3 ITGA2B MACE Interactions –
Variable | OR (CI) | OR (CI) with oCAD | OR (CI) with Aspirin | OR (CI) No reported Aspirin use (n = 622) | OR (CI) Aspirin use (n = 959) |
|---|---|---|---|---|---|
SEX | 1.95* (1.12–3.49) | 1.89* (1.03–3.46) | 1.98* (1.13–3.54) | 3.24* (1.36–8.57) | 1.4 (0.67–2.98) |
AGE | 1.04** (1.01–1.06) | 1.03* (1.00–1.06) | 1.04** (1.01–1.06) | 1.02 (0.99–1.06) | 1.05** (1.02–1.09) |
ITGA2B | 1.42* (1.00–1.97) | 1.36 (0.96–1.92) | 1.41* (1.01–1.96 | 1.23 (0.75–2.04) | 1.54 (0.98–2.44) |
oCAD | 1.44 (0.79–2.60) | ||||
ASPIRIN | 0.79 (0.46–1.38) |